EZH2 and epithelioid sarcoma: Tazemetostat (Tazverik), is an oral EZH2 inhibitor approved by the U.S. Food and Drug Administration (FDA), for the treatment of follicular lymphoma (FL) and epithelioid sarcoma (ES).